Skip to main content
logo
KalVista Pharmaceuticals, Inc. (KALV)
Jun 11, 2026 - KALV was delisted (reason: acquired by Chiesi Group)
27.00
+0.01 (0.04%)
Inactive · Last trade price on Jun 10, 2026

KalVista Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Mar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Net Income
-135.94-164.29-183.44-126.64--92.91
Depreciation & Amortization
1.561.450.940.82-0.72
Asset Writedown & Restructuring Costs
1.791.79----
Loss (Gain) From Sale of Investments
-2.58-2.8-1.55-1.23-1.13
Stock-Based Compensation
18.9517.1212.2921.92-9.92
Other Operating Activities
31.0722.863.820.75--1.53
Change in Accounts Receivable
-11.21-3.89----
Change in Inventory
-5.81-5.14----
Change in Accounts Payable
9.266.29-4.974.32-1.11
Change in Unearned Revenue
11.680.9610.56---
Change in Other Net Operating Assets
-8.083.219.4510.85-6.31
Operating Cash Flow
-89.32-122.43-152.91-89.23--75.26
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Mar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Capital Expenditures
-2.39-2.56-0.43-0.04--1.2
Sale (Purchase) of Intangibles
-0.13-0.28-0.5-0.4--
Investment in Securities
33.3730.8791.95-84.28-42.61
Investing Cash Flow
30.8428.0391.02-84.72-41.42

Financing Activities

Fiscal Year
TTMFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Mar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Total Debt Issued
208.57208.57----
Net Debt Issued (Repaid)
208.57208.57----
Issuance of Common Stock
2.132.8861.6997.59-57.03
Other Financing Activities
32.5132.5198.0453.12-1.09
Financing Cash Flow
243.2243.96159.73150.71-58.12

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Mar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Foreign Exchange Rate Adjustments
-6.67-2.752.64-1.21-1.24
Net Cash Flow
178.06146.81100.48-24.45-25.51

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Mar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Free Cash Flow
-91.71-124.99-153.34-89.27--76.46
Free Cash Flow Growth
------
Free Cash Flow Margin
-80.11%-169.79%----
Free Cash Flow Per Share
-1.69-2.32-3.09-2.43--2.74
Levered Free Cash Flow
---92.91-50.27--52.01
Unlevered Free Cash Flow
---89.29-50.27--52.01

Additional Metrics

Fiscal Year
TTMFY 2025FY 2025FY 2024FY FY 2023
Period Ending
Mar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Change in Working Capital
-4.161.4315.0415.17-7.41
SEC Filings: 10-K · 10-Q